Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19

In Mar 2020, FDA granted Gilead Science orphan drug designation for remdesivir to treat coronavirus disease 2019 even though this status is usually reserved for drugs that treat rare diseases. This Viewpoint highlights loopholes in US orphan drug policy that could be used again.


JAMA Internal Medicine